PT  - JOURNAL ARTICLE
AU  - Liao, M.
AU  - Lu, C.
AU  - Yen, Tzu-Chen
AU  - Wang, Shyh-Jen
AU  - Shan, Din-E.
AU  - Peng, Giia-Sheun
AU  - Huang, Wen-Sheng
AU  - Tseng, Y.
AU  - Wei-Lun, Hsu
AU  - Yeh, Shih-Woei
TI  - An imaging study to evaluate the D2 receptor activities and safety of I-123-IBZM SPECT in the differential diagnosis of Parkinsonian syndromes
DP  - 2011 May 01
TA  - Journal of Nuclear Medicine
PG  - 1570--1570
VI  - 52
IP  - supplement 1
4099  - http://jnm.snmjournals.org/content/52/supplement_1/1570.short
4100  - http://jnm.snmjournals.org/content/52/supplement_1/1570.full
SO  - J Nucl Med2011 May 01; 52
AB  - 1570 Objectives 123I-Iodobenzamide (123I-IBZM) functions as a dopamine D2/D3 receptor imaging agent for single photon emission computerized tomography (SPECT). The objective of this study is to evaluate the D2 receptor activities and safety of 123I-IBZM SPECT in the differential diagnosis of Parkinsonian syndromes. Methods An open-label, multi-center, non-comparative, single-arm study was designed to enroll 100 evaluable subjects aged 50 to 70 years old. Each subject underwent two sets of SPECT imaging: 99mTc-TRODAT-1 to collect the striatum uptake ratio of dopamine transporter (DAT); 123I-IBZM to evaluate the D2 receptor activities in the differential diagnosis of Parkinsonian syndromes and safety of 123I-IBZM SPECT imaging. Results A total of 100 evaluable subjects were completed for this study, including 40 IPD patients, 40 non-IPD patients (including 25 MSA patients and 15 PSP patients), and 20 normal healthy volunteers. The result of DAT imaging showed a difference in the mean striatal uptake between normal healthy volunteers and PD (IPD+non-IPD) groups. The result of D2 receptor imaging with 123I-IBZM showed increased striatal uptake in the IPD group than that in the non-IPD group. No treatment-emergent AE was observed, and no death, SAE, and other significant adverse event were reported in this study. Conclusions 123I-IBZM is generally well-tolerated and the study results demonstrated different alterations of dopamine transporter and D2 receptor function between the IPD and non-IPD group. 123I-IBZM might be a promising imaging agent to distinguish IPD and non-IPD group